Intech Biopharm (ROCO:6461) Cyclically Adjusted Book per Share: NT$15.33 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6461 Intech Biopharm Ltd ROCO:6461
55 GF Score
Price NT$15.45
GF Value NT$87.90
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Intech Biopharm Cyclically Adjusted Book per Share?

Intech Biopharm ROCO:6461 -0.64% 55 Cyclically Adjusted Book per Share is NT$15.33 as of Dec. 2025. GuruFocus rates ROCO:6461 with a GF Score™ of 55/100 and a GF Value™ of NT$87.90 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Intech Biopharm's adjusted book value per share for the three months ended in Dec. 2025 was NT$6.171. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is NT$15.33 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Intech Biopharm's average Cyclically Adjusted Book Growth Rate was -10.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-18), Intech Biopharm's current stock price is NT$15.45. Intech Biopharm's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2025 was NT$15.33. Intech Biopharm's Cyclically Adjusted PB Ratio of today is 1.01.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Intech Biopharm was 1.68. The lowest was 0.91. And the median was 1.18.


Intech Biopharm  (ROCO:6461) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Intech Biopharm's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=15.45/15.33
=1.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Intech Biopharm was 1.68. The lowest was 0.91. And the median was 1.18.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Intech Biopharm Cyclically Adjusted Book per Share Related Terms


Intech Biopharm Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Intech Biopharm's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intech Biopharm Cyclically Adjusted Book per Share Chart

Intech Biopharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 17.14 15.33

Intech Biopharm Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.14 17.00 16.51 15.97 15.33

ROCO:6461 vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Intech Biopharm's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intech Biopharm Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intech Biopharm's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Intech Biopharm's Cyclically Adjusted PB Ratio falls into.


ROCO:6461
55GF Score
Intech Biopharm Ltd ROCO:6461
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intech Biopharm Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Intech Biopharm's adjusted Book Value per Share data for the three months ended in Dec. 2025 was:

Adj_Book= Book Value per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=6.171/324.0540*324.0540
=6.171

Current CPI (Dec. 2025) = 324.0540.

Intech Biopharm Quarterly Data

Book Value per Share CPI Adj_Book
201512 20.393 236.525 27.940
201606 22.156 241.018 29.789
201609 0.000 241.428 0.000
201612 21.323 241.432 28.620
201703 0.000 243.801 0.000
201706 20.209 244.955 26.735
201709 19.083 246.819 25.054
201712 18.172 246.524 23.887
201803 19.451 249.554 25.258
201806 18.732 251.989 24.089
201809 18.079 252.439 23.208
201812 17.460 251.233 22.521
201903 16.659 254.202 21.237
201906 15.760 256.143 19.938
201909 14.790 256.759 18.666
201912 14.873 256.974 18.755
202003 14.320 258.115 17.978
202006 13.689 257.797 17.207
202009 13.101 260.280 16.311
202012 12.567 260.474 15.635
202103 11.937 264.877 14.604
202106 11.171 271.696 13.324
202109 10.499 274.310 12.403
202112 11.025 278.802 12.814
202203 10.472 287.504 11.803
202206 9.793 296.311 10.710
202209 9.209 296.808 10.054
202212 8.454 296.797 9.230
202303 7.811 301.836 8.386
202306 7.231 305.109 7.680
202309 6.709 307.789 7.064
202312 8.359 306.746 8.831
202403 7.838 312.332 8.132
202406 7.192 314.175 7.418
202409 6.505 315.301 6.686
202412 5.806 315.605 5.961
202503 5.191 319.799 5.260
202506 6.948 322.561 6.980
202509 6.064 324.800 6.050
202512 6.171 324.054 6.171

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of NT$15.33 mean?
Intech Biopharm (ROCO:6461) has a Cyclically Adjusted Book per Share of NT$15.33 as of Dec. 2025. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Intech Biopharm and its competitors.
Is Intech Biopharm's Cyclically Adjusted Book per Share too high?
Intech Biopharm's current Cyclically Adjusted Book per Share is NT$15.33. Overall, Intech Biopharm has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Intech Biopharm's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Intech Biopharm's Cyclically Adjusted Book per Share of NT$15.33 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Intech Biopharm and its competitors. Intech Biopharm's current Cyclically Adjusted Book per Share is NT$15.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intech Biopharm stock overvalued right now?
Based on GuruFocus' analysis, Intech Biopharm (ROCO:6461) is currently considered Possible Value Trap. The stock's GF Value™ is NT$87.90, compared to a current price of NT$15.45 — trading 82.4% below its estimated fair value. The current Cyclically Adjusted Book per Share is NT$15.33. Intech Biopharm's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Intech Biopharm (ROCO:6461), the current Cyclically Adjusted Book per Share is NT$15.33 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intech Biopharm (ROCO:6461) Overvalued in 2026?

Based on GuruFocus' analysis, Intech Biopharm stock appears to be undervalued. The current stock price of NT$15.45 is trading 82.4% below its estimated GF Value™ of NT$87.90. GuruFocus considers Intech Biopharm to be Possible Value Trap.

Key valuation signals for ROCO:6461:

  • Cyclically Adjusted Book per Share: NT$15.33
  • GF Value™: NT$87.90 vs. price of NT$15.45 (82.4% below fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the ROCO:6461 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Intech Biopharm Business Description

Address No.36, Ruiguang Road, 3rd Floor, Lane 358, Neihu District, Taipei, TWN, 114
Intech Biopharm Ltd is engaged in pharmaceutical R&D and sales. The company focuses on the development and manufacturing of new combinations, new formulations, and generic drugs with high barriers for the treatment of respiratory diseases. It owns the patented MDI platform iLEF (Inhaled Low Ethanol Formulation). The company operates in a single-industry segment, mainly engaged in R&D of technology and sale of pharmaceuticals.
55GF Score

Get the complete analysis for ROCO:6461

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$15.45
Price
NT$87.90
GF Value